A Phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on anti-PD-1
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma